Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line therapy in type 2 diabetes (T2D) treatments. Numero...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-08-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/treatment-progression-in-sulfonylurea-and-dipeptidyl-peptidase-4-inhib-peer-reviewed-article-PPA |
id |
doaj-536912140c054c62a4a0a2fb01e67aa4 |
---|---|
record_format |
Article |
spelling |
doaj-536912140c054c62a4a0a2fb01e67aa42020-11-24T23:39:53ZengDove Medical PressPatient Preference and Adherence1177-889X2016-08-012016Issue 11539154628352Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metforminPeng XJiang DLiu DVarnado OJBae JPXiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line therapy in type 2 diabetes (T2D) treatments. Numerous treatment pathways after metformin failure exist. It is important to understand how treatment choices influence subsequent therapy progressions. This retrospective study compares adherence to, persistence with, and treatment progression in sulfonylurea (SU) and dipeptidyl peptidase-4 (DPP-4) inhibitor patient cohorts with T2D on metformin. Methods: Using health insurance claims data, matched patient cohorts were created and OAD use was compared in patients with T2D initiating SU or DPP-4 inhibitors (index drugs) since January 1, 2010, to December 31, 2010, with background metformin therapy. Propensity score matching adjusted for possible selection bias. Persistence was measured via Cox regression as days to a ≥60-day gap in index drug possession; adherence was defined as proportion of days covered (PDC) ≥80%. Evolving treatment patterns were traced at 6-month intervals for 24 months following index drug discontinuation. Results: From among 19,621 and 7,484 patients in the SU and DPP-4 inhibitor cohorts, respectively, 6,758 patient pairs were matched. Persistence at 12 months in the SU cohort was 48.0% compared to 52.5% for the DPP-4 inhibitor cohort. PDC adherence (mean [SD]) during the 12-month follow-up period was 63.3 (29.7) for the SU cohort and 65.5 (28.7) for the DPP-4 inhibitor cohort. PDC ≥80% was 40.5% and 43.4% in the SU and DPP-4 inhibitor cohorts, respectively. A higher percentage of patients in the SU cohort remained untreated. Following index drug discontinuation, monotherapy was more common in the SU cohort, while use of two or three OADs was more common in the DPP-4 inhibitor cohort. Insulin therapy initiation was higher in the SU cohort. Conclusion: Slightly better adherence and persistence were seen in the DPP-4 inhibitor cohort. Adherence and persistence remain a challenge to many patients; understanding therapy progression will help identify target areas for intervention and improvement. Keywords: adherence, sulfonylurea, DPP-4 inhibitor, metforminhttps://www.dovepress.com/treatment-progression-in-sulfonylurea-and-dipeptidyl-peptidase-4-inhib-peer-reviewed-article-PPAadherenceoral anti-diabetic medicationtype 2 diabetes |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Peng X Jiang D Liu D Varnado OJ Bae JP |
spellingShingle |
Peng X Jiang D Liu D Varnado OJ Bae JP Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin Patient Preference and Adherence adherence oral anti-diabetic medication type 2 diabetes |
author_facet |
Peng X Jiang D Liu D Varnado OJ Bae JP |
author_sort |
Peng X |
title |
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
title_short |
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
title_full |
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
title_fullStr |
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
title_full_unstemmed |
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
title_sort |
treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin |
publisher |
Dove Medical Press |
series |
Patient Preference and Adherence |
issn |
1177-889X |
publishDate |
2016-08-01 |
description |
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line therapy in type 2 diabetes (T2D) treatments. Numerous treatment pathways after metformin failure exist. It is important to understand how treatment choices influence subsequent therapy progressions. This retrospective study compares adherence to, persistence with, and treatment progression in sulfonylurea (SU) and dipeptidyl peptidase-4 (DPP-4) inhibitor patient cohorts with T2D on metformin. Methods: Using health insurance claims data, matched patient cohorts were created and OAD use was compared in patients with T2D initiating SU or DPP-4 inhibitors (index drugs) since January 1, 2010, to December 31, 2010, with background metformin therapy. Propensity score matching adjusted for possible selection bias. Persistence was measured via Cox regression as days to a ≥60-day gap in index drug possession; adherence was defined as proportion of days covered (PDC) ≥80%. Evolving treatment patterns were traced at 6-month intervals for 24 months following index drug discontinuation. Results: From among 19,621 and 7,484 patients in the SU and DPP-4 inhibitor cohorts, respectively, 6,758 patient pairs were matched. Persistence at 12 months in the SU cohort was 48.0% compared to 52.5% for the DPP-4 inhibitor cohort. PDC adherence (mean [SD]) during the 12-month follow-up period was 63.3 (29.7) for the SU cohort and 65.5 (28.7) for the DPP-4 inhibitor cohort. PDC ≥80% was 40.5% and 43.4% in the SU and DPP-4 inhibitor cohorts, respectively. A higher percentage of patients in the SU cohort remained untreated. Following index drug discontinuation, monotherapy was more common in the SU cohort, while use of two or three OADs was more common in the DPP-4 inhibitor cohort. Insulin therapy initiation was higher in the SU cohort. Conclusion: Slightly better adherence and persistence were seen in the DPP-4 inhibitor cohort. Adherence and persistence remain a challenge to many patients; understanding therapy progression will help identify target areas for intervention and improvement. Keywords: adherence, sulfonylurea, DPP-4 inhibitor, metformin |
topic |
adherence oral anti-diabetic medication type 2 diabetes |
url |
https://www.dovepress.com/treatment-progression-in-sulfonylurea-and-dipeptidyl-peptidase-4-inhib-peer-reviewed-article-PPA |
work_keys_str_mv |
AT pengx treatmentprogressioninsulfonylureaanddipeptidylpeptidase4inhibitorcohortsoftype2diabetespatientsonmetformin AT jiangd treatmentprogressioninsulfonylureaanddipeptidylpeptidase4inhibitorcohortsoftype2diabetespatientsonmetformin AT liud treatmentprogressioninsulfonylureaanddipeptidylpeptidase4inhibitorcohortsoftype2diabetespatientsonmetformin AT varnadooj treatmentprogressioninsulfonylureaanddipeptidylpeptidase4inhibitorcohortsoftype2diabetespatientsonmetformin AT baejp treatmentprogressioninsulfonylureaanddipeptidylpeptidase4inhibitorcohortsoftype2diabetespatientsonmetformin |
_version_ |
1725511938566258688 |